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Background: Airway inflammation is mainly mediated by T helper 2 cells (Th2) that characteristically produce
interleukin (IL)-4, IL-5, and IL-13. Epidemiological studies have revealed an inverse association between the dietary
intake of vitamin A and the occurrence of asthma. Serum vitamin A concentrations are significantly lower in
asthmatic subjects than in healthy control subjects. It has been reported that all-trans retinoic acid (ATRA), a potent
derivative of vitamin A, regulates immune responses. However, its role in Th2-mediated airway inflammation
remains unclear. We investigated the effects of ATRA in a mouse model of allergic airway inflammation.
Results: We found that ATRA treatment attenuated airway inflammation and decreased mRNA levels of Th2- and
Th17-related transcription factors. The data showed that airway inflammation coincided with levels of Th2- and
Th17-related cytokines. We also showed that ATRA inhibited Th17 and promoted inducible regulatory T-cell
differentiation, whereas it did not induce an obvious effect on Th2 differentiation in vitro. Our data suggest that
ATRA may interfere with the in vivo Th2 responses via T-cell extrinsic mechanisms.
Conclusions: Administration of ATRA dramatically attenuated airway inflammation by inhibiting Th2 and Th17
differentiation and/or functions. ATRA may have potential therapeutic effects for airway inflammation in asthmatic
patients.
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Epidemiological studies have reported an inverse associ-
ation between asthma and the intake of vitamin A. Dietary
vitamin-A intake and serum vitamin-A concentrations are
significantly lower in patients with asthma than in healthy
control subjects or in people with severe asthma than in
those with mild asthma [1-3]. All-trans retinoic acid
(ATRA) is a biologically active metabolite of vitamin A
with profound effects on T-cell activation [4,5], differenti-
ation [6], and function [7,8]. ATRA binds to retinoic acid
receptors in the nucleus leading to the activation of tran-
scription of many target genes [9-11]. Emerging evidence
demonstrates that ATRA signaling is critical for T cells
differentiation and function. ATRA is an early mediator in
the development of CD4+ T cell-mediated immunity, and* Correspondence: xzw63@hotmail.com
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reproduction in any medium, provided the oralso plays a pivotal role in optimal effector and effector
memory CD8+ T cell differentiation in which vitamin A
supplementation is used to augment effector responses
[12,13]. Meanwhile, ATRA promotes Foxp3+ regulatory
T-cell (Treg) differentiation and sustains the stability and
function of natural Tregs in an inflammatory milieu. In
addition, it suppresses Th17 differentiation. ATRA and
rapamycin can synergistically increase TGF-β-mediated
Foxp3 induction in antigen-specific Th2 memory cells
when effector cytokines are neutralized. These Foxp3+ T
cells converted from Th2 memory cells possess Treg
activity and can ameliorate Th2 memory-mediated airway
hyperreactivity and eosinophilic inflammation [14-20].
Moreover, ATRA suppresses Th2-related chemokine ex-
pression in vitro by down-regulating the expression of
interleukin (IL)-5 receptor and inhibiting eosinophil and
basophil differentiation [21-23]. In addition to modulating
T cells, ATRA plays an important role in the maintenance
of the normal epithelial mucociliary phenotype [21].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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allergenic challenge has not been established. The goal of
this study is to determine whether ATRA alters Th2 re-
sponse to modulate the severity of airway inflammation in
an ovalbumin (OVA)-induced allergic airway inflamma-
tion animal model.
Results
Administration of ATRA attenuated lung inflammation
Clinical studies have shown that dietary vitamin A intake
and serum vitamin A concentrations are significantly
lower in patients with asthma than in healthy control
subjects, implicating that vitamin A might be an attract-
ive candidate for asthma treatment. ATRA is a biologic-
ally active metabolite of vitamin A [1-3]. To determine
the effects of ATRA on allergic airway inflammation, an
OVA-sensitized murine airway inflammation model was
used. The ATRA group received an intraperitoneal (i.p.)
injection of 400 μg/mouse of ATRA. The vehicle group
was injected by corn oil (vehicle group). All treatments
were administrated prior to OVA sensitization. A control
group of mice without OVA sensitization was injected
with PBS. Mice were sacrificed and lung inflammation
was evaluated at 24 hours after the final challenge (day
28). As shown in Figure 1, OVA treatment in the vehicle
group induced a substantially increase of total cells, eo-
sinophils, neutrophils, lymphocytes and macrophages
counts in bronchoalveolar lavage fluid (BALF) as com-
pared with the control group (Figure 1A), while a signifi-
cant decrease was observed after ATRA intervention
(Figure 1B, **, p < 0.05; ***, p < 0.01). Observation by
light-microscopy confirmed that OVA priming and
activation led to a marked peribronchial leukocyte, espe-
cially eosinophilic infiltration. More importantly, the in-
flammatory response was significantly attenuated after
treatment with ATRA (Figure 1C). These data indicated
that ATRA treatment mitigated the inflammatory re-
sponses in the antigen-induced allergic process.
Administration of ATRA decreased the levels of Th2 and
Th17-related cytokines, and down-regulated the
expression of corresponding transcription factors in the
lung
To determine the effects of ATRA on Th cells and the
cytokines produced by these cells after allergen stimula-
tion in the lung, IL-4, IL-5, IFN-γ, IL-10, and IL-17
levels in the lung homogenates were assessed by ELISA.
The levels of IL-4 and IL-5 in the vehicle group were
significantly elevated compared with those in the control
group (***, p < 0.001). ATRA pretreatment significantly
reduced the IL-4 and IL-5 levels and slightly decreased
the IL-17A level, but there was no significant difference
on the levels of IFN-γ or IL-10 in the compared groups
(Figure 2A). Meanwhile, real-time PCR results showedthat mRNA levels of IL-4 and IL-17A in the lung were
consistent with the ELISA results. Furthermore, the
mRNA levels of GATA-3 and RORγt were significantly
decreased in the ATRA group compared with the vehicle
group (p < 0.01), while the expression of the IFN-γ and
Th1-related transcription factor T-bet was much higher
in the ATRA group than in the vehicle group. In con-
trast with the previous in vitro results, ATRA moder-
ately increased the IL-10 mRNA level and had no effect
on the expression of the Treg-related transcription factor
Foxp3 in the lung (*, p < 0.05, Figure 2B).
Administration of ATRA suppressed the levels of Th2 and
Th17-related cytokines in draining lymph nodes
To further determine the suppressive effect of ATRA in
airway inflammation, we examined Th1, Th2, and Th17
responses in draining lymph node cells on day 28. Lym-
phocytes were isolated from mediastinal lymph nodes
and stimulated with OVA323–339 peptide for 72 hours.
The percentages of IL-4 and IFN-γ positive CD4 T cells
were analyzed by FACS. The results showed that the
number of IL-4-positive T cells significantly increased in
the vehicle group compared with the control group.
ATRA pretreatment decreased the percentages of IL-4-
positive T cells compared with the mice treated with ve-
hicle alone. However, there was no significant difference
in the percentages of IFN-γ-positive CD4 T cells be-
tween the vehicle and the ATRA group (Figure 3A). To
analyze the effects of ATRA on CD4 T-cell function, su-
pernatants from lymphocytes stimulated with OVA323-339
peptide were analyzed with ELISA. Compared with the
control mice, the levels of IL-4, IL-5, and IL-17A were
significantly increased in the vehicle mice, however,
these cytokines were dramatically decreased after pre-
treatment with ATRA (**, p < 0.001). There was no sig-
nificant difference in IFN-γ and IL-10 among the three
groups (Figure 3B).
In-vivo ATRA treatment inhibited Ag-specific Th2
responses with no obvious effect on Foxp3+ Treg
population in the spleen
Furthermore, in addition to draining lymph nodes, splenic
Th-cell populations were examined for the effects of ATRA
treatment. Splenocytes were stimulated with OVA323–339
peptide for 72 hours and then intracellularly stained with
anti-IL-4 and IFN-γ antibodies. The percentages of IL-4
and IFN-γ in gated CD4 Tcells in the spleen were analyzed
by FACS. The results showed that the percentages of IL-4-
positive T cells were significantly increased in the vehicle
group compared with the control group, while the percent-
ages of IFN-γ positive CD4 T cells were slightly decreased
in the vehicle and the ATRA treated groups compared with
the control group (Figure 4A). To examine whether ATRA
treatment could increase the Foxp3+ Treg population
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Figure 1 ATRA-attenuated lung inflammation. Mice received i.p. injection of 400 μg/mouse ATRA or vehicle on days -1, 13, 24, and 26, which
is 1 day prior to OVA sensitization, while mice were injected with PBS as control. A. The protocol used to evaluate the effects of ATRA on asthma
manifestations in vivo. B. BALF from the mice was analyzed 24 h after the final challenge (day 28). Results are shown as the total number of cells
in BAL fluid. Total, total cell number; Mac, monocyte/macrophage; Eos, eosinophils; Lym, lymphocytes; PMN, neutrophils. Values expressed as
number of cells × 105/ml or 104/ml are means ± SEM (n = 10 in each group; **, p < 0.01). Data are representative of 3 independent experiments.
C. Histopathological analyses on lung tissues from three groups at 24 hours after the final challenge (day 28). Mice were sacrificed at 24 hours
after the final challenge, lung tissues were stained with H&E, and the inflammatory cells were analyzed by light microscopy (magnification: 200×).
An increased number of eosinophils was observed in the vehicle group compared with the control group, while such an increase was obviously
attenuated in the ATRA group. Data are representative of 10 mice in each group of 3 independent experiments.
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analyzed by FACS. Unlike the effect of ATRA on conven-
tional Foxp3- CD4 T cells, ATRA treatment did not in-
crease the Foxp3+ Treg population in the spleen ofimmunized mice. These results showed that ATRA pre-
treatment decreased the percentage of IL-4-positive T cells








































































































































































































Figure 2 Administration of ATRA decreased the levels of Th2- and Th17-related cytokines and down-regulated the expression of
transcription factors in the lung. A. The levels of IL-4, IL-5, IFN-γ, IL-10, and IL-17 in the lung homogenates were assessed by ELISA. Compared
with the control group, the levels of IL-4 and IL-5 in the lung significantly elevated in vehicle group, but ATRA significantly reduced IL-4, IL-5
levels and slightly decreased the IL-7A level, but there was no significant difference for the levels of IFN-γ or IL-10 in different groups.
B. Treatment with OVA up-regulated the expression of IL-4, IL-17A mRNA in lung; ATRA suppressed these cytokine transcription levels and
increased IFN-γ and T-bet mRNA expression. Meanwhile, ATRA moderately increased the IL-10 mRNA level and had no effect on Foxp3 mRNA
transcription in vivo. Data represent the mean ± SEM with n = 10 for each group (***, p < 0.001; **, p < 0.01; *, p < 0.05). Data represent two
independent experiments.
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in vitro
To explore whether in-vivo-reduced Th2 cytokines fol-
lowing ATRA treatment was directly influenced by
ATRA, we assessed the effect of ATRA on Th2 diffe-
rentiation in vitro. Naïve CD4+CD62L+ T cells from
DO11.10 mice were cultured under a Th2-skewing con-
dition without or with different concentrations of
ATRA. After the cells were cultured for 5 days, IL-4 ex-
pression was determined by intracellular staining. Simi-
lar percentages of IL-4-producing cells were detected in
CD4 T cells with or without ATRA treatment (Figure 5),suggesting that ATRA might not influence Th2 differen-
tiation in vitro.
Discussion
Previous reports showed that ATRA is the biological ac-
tive metabolite of vitamin A and has an important im-
munomodulatory effect by inhibiting Th17 polarization
and enhancing Foxp3 expression [14-16]. By using a
murine Th2-mediated airway inflammation model, we
demonstrated that the administration of ATRA attenu-
ated OVA-induced airway inflammation by decreasing
Th2 and Th17 related cytokines and inflammatory cells
ATRAA



























































































Figure 3 Administration of ATRA suppressed the levels of Th2- and Th17-related cytokines in draining lymph nodes. A. Mice were
sacrificed at 24 hours after the final challenge and lymphocytes were isolated from mediastinal lymph nodes and stimulated with OVA323–339
peptide for 72 hours. The percentages of IL-4 positive and IFN-γ positive CD4 T cells were analyzed by FACS. The results showed that ATRA
pretreatment decreased the percentages of IL-4 positive T cells compared with the vehicle mice. B. The concentration of IL-4, IL-5, IL-10, and
IL-17A in supernatants of cultured mediastinal lymph nodes were detected by ELISA. The levels of IL-4, IL-5, and IL-17A were significantly
decreased after pretreatment with ATRA. There was no significant difference in IFN-γ and IL-10 among the three groups. Data represent the
mean ± SEM with n = 10 for each group (***, p < 0.001). Data are representative of 3 independent experiments.
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http://www.biomedcentral.com/1471-2172/14/28in the airway and ATRA mediated reduction of Th2 cy-
tokines was via inhibiting GATA-3 expression. Our find-
ings provide further supports for the anti-inflammatory
role of ATRA in the treatment of lung diseases.
OVA-induced allergic asthma is recognized as a
pathological condition that results from chronic airway
inflammation characteristically associated with the infil-
tration of lymphocytes, eosinophils, macrophages, and
neutrophils into the bronchial lumen. An aberrant Th2-
type response to allergens is characterized by the over-
production of IL-4, IL-5, and IL-13, which are critical
for the maintenance of ongoing IgE-mediated eosino-
philic inflammation [24-26]. Accumulating evidence has
suggested that aberrant IL-17 production is a key deter-
minant of severe forms of asthma. IL-17A induces lung-
structural cells to secrete proinflammatory cytokines
(TNF, IL-1β, granulocyte colony-stimulating factor, and
IL-6) and chemokines (CXCL1, CXCL2, and CXCL8/IL-8),
thereby triggering neutrophil infiltration [27-29].
We showed that the administration of ATRA inhibited
OVA mediated secretion of IL-4 and IL-5 in the lung,
draining lymph nodes, and the spleen. Consistent with
the decreased levels of Th2-related cytokines, therecruitment of inflammatory cells, especially eosinophils,
neutrophils, lymphocytes, and macrophages, was mark-
edly decreased in the BALF and the lung after ATRA ad-
ministration. These results indicated that ATRA may
alleviate airway inflammation by reducing Th2 cytokines.
Meanwhile, T-bet and GATA-3 are responsible for the
regulation of the cytokine genes during Th1/Th2 differ-
entiation. GATA-3 has been shown to promote the ex-
pression of several Th2 cytokines, including IL-4, IL-5,
and IL-13 [30,31]. It is well known that overexpression
of GATA-3 predisposes for Th2-mediated diseases such
as allergic asthma and suppression of GATA-3 expres-
sion in the lung reduces IL-4, IL-5, and IL-13 produc-
tions concurrently [30,31]. Compared with the vehicle
group, the GATA-3 mRNA level in the lung in the
ATRA treated group was significantly decreased, which
may partially explain the reduction of IL-4 and IL-5
production in these mice. In addition, a recent study
performed in chronic asthma model showed that pro-
longed ATRA treatment tends to inhibit Th17 cell infil-
tration and neutrophilia without obvious alteration of
Th2 cell numbers [32]. The different observations are

































Figure 5 Retinoic acid does not affect Th2 cells differentiation in vitro. Naïve CD4+ T cells (CD4+ CD62Lhi CD25-) were purified from
DO11.10 mice by FACS. Isolated CD4+ CD62L+T cells were stimulated with OVA peptide 323–339 in Th2 skewing condition with/without different
concentration ATRA (0.01-10 μmol/L) for 3 days. The cells were then stained with CD4 and IL-4 antibodies and analyzed by FACS. Dot-plot



































































































Figure 4 ATRA treatment inhibited Ag-specific Th2-cell responses and had no effect on Foxp3+ Treg population in spleen. Mice were
sacrificed at 24 hours after the final challenge. A. Spleenocytes were isolated from spleens and stimulated with OVA323–339 peptide for 72 hours,
then intracellular stained with indicated antibodies after stained with the extracellular maker CD4. The percentages of IL-4 and IFN-γ positive CD4
T cells in the spleen were analyzed by FACS. B. Spleenocytes were isolated from spleens stained for the extracellular maker CD4, CD25 and
intracellular markers Foxp3 and analyzed by FACS. The percentages of Treg cells (CD25+ Foxp3+) were gated on CD4+ T cells, The results showed
that ATRA pretreatment decreased the percentages of IL-4 positive T cells but no effect on Treg cell population. Data represent five mice of each
group in three independent experiments.
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sponses are mediated by different Th subsets.
The concentration of retinoic acid is likely to be critical
to its effect on the airway responses. Previous studies have
demonstrated that ATRA reverses the airway hyper-
responsiveness (AHR) and exogenous administration of
retinoic acid is capable of attenuating the asthma pheno-
type [32-34]. However, it has also been reported that
ATRA promotes Th2 development to exacerbate allergic
immune and inflammatory responses during systemic
sensitization [35]. The differences in the responses of the
airway are probably linked to the different concentrations
and time point used in those studies. Indeed, the study
performed by Mateu et al. supports the above notion.
They have found that retinoic acid directly enhances aller-
gic responses in vivo, but higher doses effectively decrease
AHR by inhibiting IL-5 production [36]. Therefore, the
concentration and time point of retinoic acid should be
carefully considered in the applications.
Of note, ATRA was not able to affect Th2 differenti-
ation in a Th2 skewing condition in vitro. The discrep-
ancy between the effects of ATRA on in-vitro and
in-vivo Th2 responses suggested that ATRA might not
intrinsically control Th2 differentiation. Rather, it might
do so by inhibiting the Th17 response or by modulating
the function of antigen presenting cells. In addition,
Bidad K et al. have reported that ATRA can significantly
decrease Th17 cells in patients with ankylosing spondyl-
itis. The effect of ATRA in such patients serves as an
immunomodulator on deviated immune cells, which is
associated with decreased inflammatory cytokine TNF-α
secretion [36]. In our study, we also found that the level
of IL-17A was slightly decreased in the draining lymph
nodes and lung, while IFN-γ and T-bet mRNAs were
slightly increased in the lung after the administration of
ATRA. Unlike the in-vitro results previously reported
by Elias et al. [15], our in vivo data showed that ATRA
moderately increased IL-10 expression without affecting
IL-10 production, Foxp3 expression and Treg numbers
in the lung or spleen. The different responses of Treg
cells might be attributed to the difference between the
in-vivo environment and in-vitro condition [32]. Add-
itionally, ATRA effects on Treg cells in vivo might be
also influenced by the exposure time of ATRA. For ex-
ample, Zhao et al. found that the proportion of Foxp3+
CD4 Treg cells in the lymph nodes is temporarily in-
creased after a week of ATRA treatment [32]. The data
suggest that ATRA may affect Treg cells in a context-
and time-dependent manner.
Conclusions
In summary, ATRA administration significantly de-
creased Th2- and Th17-related cytokines and markedly
reduced airway inflammation in a murine allergic airwayinflammation model. These findings suggested that
ATRA may serve as an effective therapy for allergic air-
way inflammation. Our study suggested potential bene-
fits of Vitamin-A supplement for asthma patients and
may provide the basis for further investigation of the
mechanisms underlying the potential therapeutic effects




A total of 90 female BALB/c mice and 3 DO11.10 mice at
6 ~ 8 weeks of age were purchased from the Shanghai
SLAC Laboratory Animal Company. All mice were main-
tained under specific pathogen-free conditions in our ani-
mal facility. BALB/c mice were randomly divided into 3
groups: a control group, OVA plus vehicle (vehicle group),
and OVA-plus ATRA (ATRA group). Each group included
10 mice, and 3 independent experiments were performed.
Animal experiments were performed according to the
Ethics Committee of Ruijin Hospital, Shanghai Jiaotong
University School of Medicine.
Ag sensitization and challenge protocol and
administration of ATRA
The mouse-asthmatic model was established as de-
scribed previously [37,38]. In both vehicle and ATRA
groups, mice received i.p. injections of 100 μg OVA
(Sigma-Aldrich) in 0.2 ml Al(OH)3 adjuvant suspension
on days 0 and 14. On days 14, 25, 26, and 27, mice were
anesthethized with isoflurane and intranasally received
100 μg of OVA in 0.05 ml phosphate buffer saline (PBS)
(days 14) and 50 μg of OVA in 0.05 ml PBS (days 25, 26,
and 27). The control group was sensitized with the same
volume of Al(OH)3 and challenged with normal saline
instead of OVA. ATRA was dissolved in dimethyl sulfox-
ide (DMSO) and diluted in corn oil. Mice in the ATRA
group received i.p. injections of 400 μg ATRA on days –1,
13, 24, and 26, the latter being one day prior to OVA
sensitization. The mice in the vehicle group were injected
with the same volume of corn oil.
Bronchoalveolar lavage fluid (BALF)
Twenty-four hours after the final challenge (day 28),
BALB/c mice were sacrificed by CO2. BALF was
obtained by the slow injection of 0.4 ml ice-cold PBS
into the trachea using a 22-inch i.v. with cathetering
three times (total 1.2 ml). This procedure recovered 80
to 90% of the infused fluid. The total number of cells in
BALF was counted using a hemacytometer. After cytospin,
the cells were fixed and stained by hematoxylin-eosin
(H&E). A total of 200 cells were randomly selected to
calculate eosinophils, neutrophils, lymphocytes and
macrophages under the microscope (Olympus AX70,
Wu et al. BMC Immunology 2013, 14:28 Page 8 of 10
http://www.biomedcentral.com/1471-2172/14/28Japan). Different cell counts were calculated by the fol-
lowing equation:
Total number ¼ number of target cell under theð
microscope=200Þ  total cell count
Histology
The lung lobe was fixed in 10% formalin, embedded in
paraffin, and sectioned in 4 μm slices. Sections were
stained with H&E and examined microscopically.
Detection of soluble cytokine levels in lung
To determine soluble cytokine levels in the lungs, a
snap-frozen right lung lobe from each mouse was
thawed on ice and homogenized in a buffer containing a
protein-protease inhibitor and 0.1% Triton X-100. The
samples were centrifuged, and 50 μl of cell-free super-
natant was analyzed by ELISA according to the manu-
facturer’s instructions. Cytokine levels including IL-4,
IL-5, interferon (IFN)-γ, IL-10 and IL-17 in the culture
supernatants of mediastinal lymph nodes, splenocytes
and lung homogenates were quantified. All the anti-
bodies for the assay were purchased from Biolegend.
Cells stimulation and cytokines assay in vitro
Lymphocytes and splenocytes were used to determine
the immune-regulatory effects of ATRA. On day 28, the
mice were sacrificed and mediastinal lymph nodes and
spleens were isolated. The cell clumps were disag-
gregated into single-cell suspensions using nylon mesh
(30 μm) filtration. Red blood cells were removed by a
red-blood-cell lysis buffer. The isolated lymphocytes
and splenocytes were cultured in a 0.5 ml RPMI 1640
medium (Sigma-Aldrich) supplemented with 2 mmol/L
L-glutamine, 10% fetal calf serum (FCS), 100 mg/ml
streptomycin, 100 IU/ml penicillin, 10 mm HEPES, and
20 mm sodium hydrogen carbonate (Invitrogen Life Tech-
nologies, Carlsbad, California, USA). Lymphocytes and
splenocytes were cultured at the density of 2 × 106/ml in
48 well plates under the stimulation with 10 μg/ml
OVA323–339 peptide for 72 hours. The cells were harvested
and intracellular staining for IFN-γ, IL-4, and IL-17A were
performed for flow cytometry. The cell supernatants were
collected and analyzed for IFN-γ, IL-4, IL-5, IL-17A, and
IL-10 using mouse ELISA kits (Biolegend).
Real-time PCR analysis
For the total RNA isolation, lung tissue was removed
from the animal, immediately froze in liquid N2, and
stored at –70°C for assaying. The frozen lung tissue was
then homogenized in TRIzol reagent (Invitrogen Life
Technologies, Carlsbad, California, USA), and the total
RNA was isolated according to the manufacturer’sinstructions. Reverse transcription was performed using
40 ng of the total RNA with Superscript III RT kit
(Qiagen) and oligo(dT) primers (Invitrogen Life Tech-
nologies, Carlsbad, California, USA) as recommended by
the manufacturer. The Bio-Rad quantitative PCR SYBR
Green Master Mix (Bio-Rad Laboratories) was used and
performed the following program: 95°C for 5 min and
40 cycles of amplification at 95°C for 15 seconds and 58°C
for 60 seconds. Relative levels of target mRNA were
compared with β-actin using the 2−ΔΔCt method. Primer
sequences were obtained from Integrated DNA Technolo-
gies. Sequences were as follows: β-actin Forward: 5′-GGC
TGT ATT CCC CTC CAT CG-3′, Reverse: 5′-CCA GTT
GGT AAC AAT GCC ATG T-3′; IL-4 Forward: 5′-GGT
CTC AAC CCC CAG CTA GT-3′, Reverse: 5′-GCC GAT
GAT CTC TCT CAA GTG AT-3′; IL-10 Forward: 5′-
GCT CTT ACT GAC TGG CAT GAG-3′, Reverse: 5′-
CGC AGC TCT AGG AGC ATG TG-3′; IL-17A Forward:
5′-TTT AAC TCC CTT GGC GCA AAA-3′, Reverse:
5′-CTT TCC CTC CGC ATT GAC AC-3′; IFN-γ For-
ward: 5′-ATG AAC GCT ACA CAC TGC ATC-3′, Re-
verse: 5′-CCA TCC TTT TGC CAG TTC CTC-3′;
Foxp3 Forward: 5′-CAC AAT ATG CGA CCC CCT
TTC-3′, Reverse: 5′-AAC ATG CGA GTA AAC CAA
TGG TA-3′.
In-vitro Th2 differentiation assays
Naïve CD4+ T cells were isolated from 3 DO11.10 mice,
and a single-cell suspension was prepared by grinding
spleen against a 70-μm nylon cell strainer. After lysis of
red cells by red-blood-cell lysis buffer, naïve CD4+ T cells
(CD4+ CD62Lhigh CD25-) were first purified by a Mouse
CD4+ T Cell Isolation Kit (Miltenyi Biotech) and followed
by FACS-sorting. Cells were seeded in 48-well plates for
further experiments. The seeding density was 2 × 105 naïve
T cells/well.
Naïve T cells were maintained in RPMI 1640 (Invitrogen
Life Technologies, Carlsbad, CA) supplemented with
2 mmol/L L-glutamine, 10% fetal-calf serum (FCS),
100 mg/ml streptomycin, 100 IU/ml penicillin, 10
mm HEPES, and 20 mm sodium hydrogen carbonate
(Invitrogen Life Technologies, Carlsbad, California,
USA). The cells were activated with plate-bound anti-
CD3 (2 μg/ml), and soluble anti-CD28 (2 μg/ml) anti-
bodies (BD PharMingen). Th-neutral conditions (Th0)
contained no exogenous cytokines or anti-cytokines.
Th2 conditions contained 10 ng/ml IL-4 (R&D Sys-
tems) with 10 μg/ml anti-IFN-γ (BD PharMingen).
Where indicated, IL-2 was added at 100 IU/ml. All
ATRA (Sigma, St Louis, MO) were dissolved in di-
methyl sulfoxide (DMSO) at stock concentrations of
0.01 M and stored at −80°C in light-proof containers.
Stocks were thrown away after 4 freeze-thaw cycles.
Cultures containing ATRA were protected from light
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wise, ATRA was used at different concentration from
0.01, 0.05, 0.1, 0.5, 1, 2.5, 5 to 10 μmol/L.
Statistics
Data are presented as mean ± SEM. The differences be-
tween mean values were calculated using student’s t test,
and a p value of less than 0.05 was considered signifi-
cant. All experiments were repeated at least 3 times, and
n = 10 in each experimental group.
Abbreviations
ATRA: All-trans retinoic acid; BALF: Bronchoalveolar lavage fluid; AHR: Airway
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